Afyonkarahisar Merkez

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3, randomized, placebo-controlled study to see if it can reduce the risk of major adverse cardiovascular events (MACE-PLUS) in adults with established atherosclerotic cardiovascular disease (ASCVD) or those at high risk for a first ASCVD event. The study compares AZD0780 to a placebo and monitors participants from randomization until the primary analysis censoring date, followed by a final study closure visit. Participants will be randomly assigned to receive either oral AZD0780 or an oral placebo once daily. The treatment period lasts until the primary analysis censoring date, after which a study closure visit will occur. The study is event-driven and designed to assess the time to the first major cardiovascular event during treatment. During the study, participants will be closely monitored with various assessments to evaluate cardiovascular outcomes and safety over approximately 54 months. Researchers will track the time to first event of any component of MACE-PLUS and collect data to assess the effect of AZD0780 compared to placebo. The study includes regular visits and evaluations to ensure participant safety and adherence to treatment.

Researchers are investigating whether ziltivekimab can treat people living with heart failure and inflammation. The study compares ziltivekimab, a new medicine not yet approved anywhere, to a placebo, an inactive substance that looks like the medicine but contains no active drug. Participants have an equal chance of receiving either treatment. The study is expected to last up to one year and four months and focuses on people with heart failure who also have systemic inflammation. Participants will receive either ziltivekimab or placebo by monthly injections under the skin. The doses are given once a month throughout the study period. The study lasts for 12 months of treatment following randomization, during which the effects of the medicine compared to placebo will be closely monitored. During the study, participants will undergo various assessments including a heart failure questionnaire called the Kansas City Cardiomyopathy Questionnaire (KCCQ) to measure symptoms and physical function over the 12 months. Other evaluations may include walking tests and heart function tests. Safety and health will be monitored regularly to understand how participants respond to the treatments and to track any side effects or changes in heart failure symptoms.

Researchers are evaluating ziltivekimab as a treatment for people living with heart failure and inflammation. This Phase 3 study compares ziltivekimab to a placebo in participants with heart failure who have mild to preserved ejection fraction and systemic inflammation. The study aims to assess the effect of ziltivekimab on cardiovascular death, heart failure hospitalization, or urgent heart failure visits over a period of up to 4 years. Participants will receive monthly injections of either ziltivekimab or a placebo using a pre-filled syringe or a pen-injector. The study medication is administered subcutaneously once a month for up to 4 years. The trial includes up to 20 clinic visits during which participants will be monitored and assessed. During the study, participants will use a study app on their phone to record all injections and complete questionnaires. Researchers will monitor participants for key outcomes like cardiovascular events and heart failure episodes from the time of randomization until the end of the study. Safety and health status will be regularly evaluated throughout the study period, which may last up to 48 months.

Researchers are evaluating the effect of a triple therapy inhaler called BGF MDI containing budesonide, glycopyrronium, and formoterol fumarate compared with a dual therapy inhaler called GFF MDI containing glycopyrronium and formoterol fumarate in people with Chronic Obstructive Pulmonary Disease (COPD) who have a higher risk of heart and lung problems. This Phase III randomized, double-blind, parallel group study takes place at multiple centers and focuses on cardiopulmonary outcomes in these patients. Participants receive either the BGF MDI 320/14.4/9.6 micrograms twice daily or the GFF MDI 14.4/9.6 micrograms twice daily. The treatments are inhaled using metered dose inhalers. The study compares these two therapies over time to see how they affect the time until the first severe heart or lung event occurs. The study design ensures that neither participants nor researchers know which treatment is given to reduce bias. During the study, participants will have regular visits to the study site or virtual visits to complete assessments. Researchers will monitor lung function, symptoms, and blood tests, including blood eosinophil counts and COPD assessment test scores. The main outcome measured is the time to the first severe cardiac or COPD event, with follow-up lasting up to three years. Safety and adherence to treatment will also be closely observed throughout the study period.

Researchers are evaluating the effects of the drug orforglipron compared with a placebo on cardiovascular outcomes in adults who have atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). This is a Phase 3, randomized, double-blind, placebo-controlled study designed to investigate major adverse cardiovascular events over a long period. Participants will receive either orforglipron or a placebo orally. The study is event-driven and will continue until the occurrence of major cardiovascular events or up to about 5 years. The treatments are administered without revealing to participants which group they are in to ensure unbiased results. During the study, participants will be monitored for the time to the first occurrence of a major cardiovascular event. Researchers will collect data from baseline through the end of the study, which lasts approximately 5 years. Regular assessments will help evaluate the safety and effects of the treatments on cardiovascular health in this population.

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.

Researchers are evaluating whether ziltivekimab can help people who were hospitalized due to a heart attack by potentially reducing the development of heart disease and preventing new heart attacks or strokes. This Phase 3 study compares ziltivekimab with a placebo, which is a dummy medicine that has no effect on the body. Both treatments are given by chance, with equal likelihood for participants to receive either ziltivekimab or placebo. Participants will inject the study medicine once a month under the skin in the stomach, thigh, or upper arm. Ziltivekimab is given as an initial loading dose followed by monthly maintenance doses. The placebo group receives a matching injection schedule. The study duration is about two years. During the study, researchers will monitor participants for the time until the first serious heart-related event, including cardiovascular death, non-fatal heart attack, or non-fatal stroke. Participants will be closely observed from the start of randomization up to 25 months. The study includes regular follow-ups to assess safety and effectiveness of the treatments throughout this period.

Carpal tunnel syndrome (CTS) is a common nerve compression condition causing numbness, tingling, muscle weakness, and hand atrophy. Researchers are evaluating and comparing the effects of rest splints and high-intensity laser therapy (HILT), both added to physical therapy programs, on pain, function, nerve conduction studies, and grip strength in patients with CTS. This study is designed as a prospective randomized controlled trial enrolling adults diagnosed with CTS. Participants will be randomly assigned to one of three groups. The first group receives a physical therapy program including wrist range of motion exercises, muscle strengthening, stretching, nerve and tendon gliding exercises, and grip strengthening, along with wearing a resting splint designed to hold the wrist in a neutral position for 6 weeks, five days a week, totaling 30 sessions. The second group receives the same physical therapy plus high-intensity laser therapy using the HIRO 3 device five days a week for 6 weeks (30 sessions). The third group receives the physical therapy with sham laser treatment, where the device is turned on but emits no laser. Throughout the study, participants will have their pain measured using the Visual Analog Scale (VAS) at baseline, after 6 weeks, and after 12 weeks post-treatment. Researchers will assess function, nerve conduction, and grip strength as part of the outcome evaluations. The study involves close monitoring of treatment effects over the 6-week intervention and follow-up periods to compare the benefits of rest splints versus high-intensity laser therapy combined with physical therapy in managing carpal tunnel syndrome.

Researchers are comparing the effects of three different therapies—mirror therapy, Repetitive Transcranial Magnetic Stimulation (rTMS), and robot-assisted hand therapy—when added to conventional neurological rehabilitation for stroke patients. The goal is to see how these treatments impact upper limb function, pain, and quality of life in people who have experienced a stroke. Stroke often leads to long-term disability affecting daily activities and quality of life, so new rehabilitation methods are being studied to improve these outcomes. Participants will be divided into three groups, each receiving 20 sessions over 4 weeks (5 times per week) of conventional neurological rehabilitation. The first group will also receive mirror therapy sessions for the upper extremity, the second group will receive low-frequency (1 Hz) rTMS applied to the motor cortex region controlling the affected arm using the Magventure MagPro R30 device, and the third group will undergo robot-assisted hand therapy using the AMADEO device to support passive and active exercises for the affected hand. During the study, participants will undergo several assessments before and after the 4-week treatment, including physical and neurological evaluations, motor function tests like the Fugl Meyer Upper Extremity Assessment, quality of life questionnaires, pain scales, and depression and anxiety inventories. Researchers will monitor upper limb function, pain levels, and quality of life to compare the effects of the three therapies alongside conventional rehabilitation. The total participation duration is 4 weeks of treatment with evaluations at baseline and post-treatment.

Carpal tunnel syndrome (CTS) is a common nerve compression disorder affecting the median nerve in the wrist, leading to symptoms like numbness, tingling, weakness, and pain. This research aims to compare two treatments for mild, moderate, and severe CTS: ultrasound-guided perineural injection around the median nerve and classic minimal incision surgery to relieve pressure on the nerve. The study evaluates which approach may better improve symptoms and function in affected individuals. Participants will receive either an ultrasound-guided injection of 5 cc of 5% dextrose around the median nerve at the carpal tunnel entrance or undergo a minimal incision surgical procedure to decompress the median nerve. The ultrasound injection is done using a precise technique to avoid damaging nearby blood vessels, while the surgery involves a small cut to release the nerve pressure. Both treatments are aimed at reducing symptoms by addressing nerve compression. During the study, participants will be monitored at baseline, 4 weeks, and 12 weeks to measure changes in wrist pain using a visual analog scale. Researchers will assess symptoms, nerve function, and safety throughout the study period. The total participation duration includes these follow-ups to evaluate the effects of each treatment approach on pain relief and nerve health.